生长抑素及蛋白酶抑制剂用于预防ERCP术后胰腺炎及高淀粉酶血症的贝叶斯网状Meta分析(6)
[18] GONG LJ. Somatostatin versus endoscopic nasal biliary drainage in the prevention of post-ERCP pancreatitis and hyperamylasemia[J]. World Chi J Digestol，2012，20(25)：2427-2431.
[19] KWON YH， KIM JY， LEE SJ， et al. Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis？[J]. Korean J Gastroenterol， 2012， 59(3)：232-238.
[20] PARK KT， KANG DH， CHOI CW， et al. Is high-dose nafamostat mesilate effective for the prevention of post- ERCP pancreatitis， especially in high-risk patients？[J]. Pancreas， 2011， 40(8)：1215-1219.
, 百拇医药
[21] YOO KS， HUH KR， KIM YJ， et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis： a prospective， randomized， double-blind， controlled trial[J]. Pancreas， 2011， 40(2)：181-186.
[22] MOON SW， KIM TH， JI HJ， et al. Prophylactic effect of Nafamostat on post ERCP pancreatitis： prospective， Randomized， Placebo-controlled trial[J]. Eur J Gastroenterol Hepatol，2010， 25：A65-A65.
, 百拇医药 [23] WEI C， YING C， YANG J， et al. Clinical study of prophylactic effect of proton pump inhibitor combined with somatostatin and gabexate on post-ERCP pancreatitis and hyperamylasemia[J]. Chi J Gastroenterol， 2009， 14(7)：414-417.
[24] CHOI CW， KANG DH， Kim HW， et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis[J]. Gastrointest Endosc， 2009， 69(4)：e11.
[25] CHAN HH， LAI KH， LIN CK， et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography[J]. J Chin Med Assoc， 2008， 71(12)：605-609.
, 百拇医药
[26] LEE KT， LEE DH， YOO BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis： a randomized， multicenter controlled trial[J]. Pancreas，2008，37(4)：445-448.
[27] KENICHIRO U， YOSHIAKI M， YASUO H， et al. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy[J]. J Surg Oncol， 2008， 98(5)：309-313.
, 百拇医药
[28] YOO JW， RYU JS， WOO S， et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients： a prospective， randomized， placebo-controlled trial[J]. Pancreas， 2008， 37(4)：366-370.
[29] GIANPIERO M， SANDRO A， GIOVANNI L， et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis： a randomized， controlled， multicenter study[J]. Gastrointest Endosc， 2007， 65(7)：982-987., http://www.100md.com(陈健刚 张丹丹 吕旭峰 杨悦)
[19] KWON YH， KIM JY， LEE SJ， et al. Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis？[J]. Korean J Gastroenterol， 2012， 59(3)：232-238.
[20] PARK KT， KANG DH， CHOI CW， et al. Is high-dose nafamostat mesilate effective for the prevention of post- ERCP pancreatitis， especially in high-risk patients？[J]. Pancreas， 2011， 40(8)：1215-1219.
, 百拇医药
[21] YOO KS， HUH KR， KIM YJ， et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis： a prospective， randomized， double-blind， controlled trial[J]. Pancreas， 2011， 40(2)：181-186.
[22] MOON SW， KIM TH， JI HJ， et al. Prophylactic effect of Nafamostat on post ERCP pancreatitis： prospective， Randomized， Placebo-controlled trial[J]. Eur J Gastroenterol Hepatol，2010， 25：A65-A65.
, 百拇医药 [23] WEI C， YING C， YANG J， et al. Clinical study of prophylactic effect of proton pump inhibitor combined with somatostatin and gabexate on post-ERCP pancreatitis and hyperamylasemia[J]. Chi J Gastroenterol， 2009， 14(7)：414-417.
[24] CHOI CW， KANG DH， Kim HW， et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis[J]. Gastrointest Endosc， 2009， 69(4)：e11.
[25] CHAN HH， LAI KH， LIN CK， et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography[J]. J Chin Med Assoc， 2008， 71(12)：605-609.
, 百拇医药
[26] LEE KT， LEE DH， YOO BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis： a randomized， multicenter controlled trial[J]. Pancreas，2008，37(4)：445-448.
[27] KENICHIRO U， YOSHIAKI M， YASUO H， et al. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy[J]. J Surg Oncol， 2008， 98(5)：309-313.
, 百拇医药
[28] YOO JW， RYU JS， WOO S， et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients： a prospective， randomized， placebo-controlled trial[J]. Pancreas， 2008， 37(4)：366-370.
[29] GIANPIERO M， SANDRO A， GIOVANNI L， et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis： a randomized， controlled， multicenter study[J]. Gastrointest Endosc， 2007， 65(7)：982-987., http://www.100md.com(陈健刚 张丹丹 吕旭峰 杨悦)